Development of combination therapies with BTK inhibitors and dasatinib to treat CNS-infiltrating E2A-PBX1+/preBCR+ ALLGaia Gentile(University of Freiburg), Jesús Duque‐Afonso(University of Freiburg)Blood AdvancesApril 10, 202410.1182/bloodadvances.2023011582Cited by 8SaveCiteExport RISWatch citationsRelated PapersFunctional Characterization of Transforming Growth Factor-β Signaling in Dasatinib Resistance and Pre-BCR+ Acute Lymphoblastic Leukemia|Cancers|2023|4